Pluribus, the acclaimed Vince Gilligan medical drama starring Rhea Seehorn on Apple TV+, earned a robust 18 Emmy nominations for its freshman season—more than any prior Gilligan newcomer—positioning it as a technical and creative contender despite trailing frontrunners like The Pitt in overall buzz. Trader consensus favoring 2-5 wins reflects strong precursor signals in writing, directing, and supporting categories alongside Seehorn’s solid lead actress prospects, tempered by historical patterns where new series rarely sweep against established dramas. Recent guild and critics momentum has been modest post-nominations, with no major late surges or upsets reported, leaving room for technical awards but highlighting barriers in series and major acting races. Upcoming ceremonies will test whether the show’s distinctive narrative edges out competitors.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоHow many Emmys will “Pluribus” win?
2-3 39%
4-5 31%
0-1 18%
6-7 9%
0-1
18%
2-3
39%
4-5
31%
6-7
9%
8-9
7%
10+
5%
2-3 39%
4-5 31%
0-1 18%
6-7 9%
0-1
18%
2-3
39%
4-5
31%
6-7
9%
8-9
7%
10+
5%
This market will resolve according to the number of Emmys won by "Pluribus," or by people for their roles in "Pluribus," awarded during the live Primetime Emmy Awards ceremony, expected to be held on September 14, 2026. Awards presented at the Creative Arts Emmy Awards (September 5–6, 2026) will not count toward this market's resolution.
Each award will count once even if it has multiple recipients.
If the Primetime Emmys are partially awarded by September 30, 2026, 11:59 PM ET, this market will resolve according to the number of awards won by the specified show up until that point. If, for any reason, no winners are declared by September 30, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
The primary resolution source for this market will be official information from the Academy of Television Arts & Sciences and the Emmys, including data from their websites (e.g. https://theemmys.tv/, https://www.televisionacademy.com/) and the live broadcast of the award ceremony, however a consensus of credible reporting may also be used.
Ринок відкрито: Jul 31, 2026, 7:28 PM ET
Resolver
0x69c47De9D...This market will resolve according to the number of Emmys won by "Pluribus," or by people for their roles in "Pluribus," awarded during the live Primetime Emmy Awards ceremony, expected to be held on September 14, 2026. Awards presented at the Creative Arts Emmy Awards (September 5–6, 2026) will not count toward this market's resolution.
Each award will count once even if it has multiple recipients.
If the Primetime Emmys are partially awarded by September 30, 2026, 11:59 PM ET, this market will resolve according to the number of awards won by the specified show up until that point. If, for any reason, no winners are declared by September 30, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
The primary resolution source for this market will be official information from the Academy of Television Arts & Sciences and the Emmys, including data from their websites (e.g. https://theemmys.tv/, https://www.televisionacademy.com/) and the live broadcast of the award ceremony, however a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...Pluribus, the acclaimed Vince Gilligan medical drama starring Rhea Seehorn on Apple TV+, earned a robust 18 Emmy nominations for its freshman season—more than any prior Gilligan newcomer—positioning it as a technical and creative contender despite trailing frontrunners like The Pitt in overall buzz. Trader consensus favoring 2-5 wins reflects strong precursor signals in writing, directing, and supporting categories alongside Seehorn’s solid lead actress prospects, tempered by historical patterns where new series rarely sweep against established dramas. Recent guild and critics momentum has been modest post-nominations, with no major late surges or upsets reported, leaving room for technical awards but highlighting barriers in series and major acting races. Upcoming ceremonies will test whether the show’s distinctive narrative edges out competitors.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання